Unraveling ADC resistance in hematologic malignancies: Challenges and new frontiers
- 22 December 2025
- journal article
- review article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 278, 156341
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- Targeted and epigenetic therapies for acute myeloid leukemia treatmentDiscover Oncology, 2025
- Multiple Myeloma UnpackedHematological Oncology, 2025
- Hodgkin lymphoma: 2025 update on diagnosis, risk‐stratification, and managementAmerican Journal of Hematology, 2024
- In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirineeJHaem, 2023
- Philadelphia-like acute lymphoblastic leukemia: the journey from molecular background to the role of bone marrow transplant—review articleAnnals of Hematology, 2023
- GSK3 inhibitor enhances gemtuzumab ozogamicin‐induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistanceeJHaem, 2022
- Diagnosis and Management of Multiple MyelomaJAMA, 2022
- Biology and Treatment of Hairy Cell LeukemiaCurrent Treatment Options in Oncology, 2020
- Antibody–Drug Conjugates for the Treatment of Hematological Malignancies: A Comprehensive ReviewTargeted Oncology, 2018
- New insights into mechanisms of resistance to microtubule inhibitorsBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2011